Sector News

Allergan to buy medical device company Keller Medical Inc.

June 8, 2017
Life sciences

Allergan PLC said early Wednesday that it plans to buy privately-held medical device company Keller Medical Inc., which developed a funnel used during breast surgery procedures.

The Keller Funnel, which helps plastic surgeons guide implants into the surgical pocket and reduces the risk of implant contamination, is “a natural complement to our world-class plastic surgery and regenerative medicine business,” said Senior Vice President of Medical Aesthetics David Moatazedi.

Plastic surgery and cosmetics has become a key business area for Allergan, with its aesthetics business — which includes Botox among other products — seen as one of its key assets. Allergan spent nearly $2.5 billion earlier this year to buy body-contouring company Zeltiq Aesthetics. Allergan shares were not active in premarket trade. Shares have dropped 4.7% over the last three months, compared with a 2.6% rise in the S&P 500.

By Emma Court

Source: Market Watch

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach